Our Team

We believe that oRNA is the future of RNA therapeutics and have built the right team to execute on this vision. Our team possesses deep expertise in research and drug development with a clear focus to define a new class of RNA therapies.

Thomas M. Barnes, PhD
Chief Executive Officer
John J. McCabe, CPA
Chief Financial Officer
Greg Motz, PhD
VP, Head of Biology
Brian Goodman, PhD
Interim VP, Business Development
Daniel Anderson, PhD
Professor, Massachusetts Institute of Technology
Sakae Asanuma, CFA
President, Taiho Ventures
Thomas M. Barnes, PhD
CEO, Orna Therapeutics
Shinichiro Fuse, PhD
Partner, MPM Capital
Ansbert Gadicke, MD
Chairman of the Board, Co-founder & Managing Director, MPM Capital
Morana Jovan-Embiricos
Managing Partner, F2 Ventures
Francesco Marincola, MD
SVP and Global Head of Cell Therapy Research, Kite, a Gilead Company
Alex Wesselhoeft, PhD
Director, Molecular Biology, Inventor
Raffaella Squilloni, MBA
Director, Business Development
Daniel Anderson, PhD
Professor, Massachusetts Institute of Technology